Member Exclusive

HealthCore and Novo Nordisk to collaborate on long-term pragmatic clinical trial of Ozempic in Type 2 diabetic patients

HealthCore Inc. (DE, USA) and Nordisk Inc. (Bagsværd, Denmark) have plans for a randomized pragmatic clinical trial of Ozempic (semaglutide) for Type 2 diabetic patients to analyze its long-term effectiveness and real-world benefits.

Go to the profile of The Evidence Base
Apr 15, 2019
0
0

Please sign in or register for FREE

No comments yet.